Critical role for glycosphingolipids in Niemann-Pick disease type C

Mark Zervas, Kyra L. Somers, Mary Anna Thrall, Steven U. Walkley

Research output: Contribution to journalArticle

246 Citations (Scopus)

Abstract

Niemann-Pick type C (NPC) disease is a cholesterol lipidosis caused by mutations in NPC1 and NPC2 gene loci [1]. Most human cases are caused by defects in NPC1 [2], as are the spontaneously occurring NPC diseases in mice [3] and cats [4]. NPC1 protein possesses a sterol-sensing domain [1-3] and has been localized to vesicles that are believed to facilitate the recycling of unesterified cholesterol from late endosomes/lysosomes to the ER and Golgi [1, 5-7]. In addition to accumulating cholesterol, NPC1-deficient cells also accumulate gangliosides and other glycosphingolipids (GSLs), and neuropathological abnormalities in NPC disease closely resemble those seen in primary gangliosidoses [1, 8-12]. These findings led us to hypothesize that NPC1 may also function in GSL homeostasis [9]. To evaluate this possibility, we treated murine and feline NPC models with N-butyldeoxynojirimycin (NB-DNJ), an inhibitor of glucosylceramide synthase, a pivotal enzyme in the early GSL synthetic pathway [13, 14]. Treated animals showed delayed onset of neurological dysfunction, increased average life span (in mice), and reduced ganglioside accumulation and accompanying neuropathological changes. These results are consistent with our hypothesis and with GSLs being centrally involved in the pathogenesis of NPC disease, and they suggest that drugs inhibiting GSL synthesis could have a similar ameliorating effect on the human disorder.

Original languageEnglish (US)
Pages (from-to)1283-1287
Number of pages5
JournalCurrent Biology
Volume11
Issue number16
DOIs
StatePublished - Aug 21 2001

Fingerprint

Type C Niemann-Pick Disease
glycosphingolipids
Glycosphingolipids
gangliosides
Gangliosides
Cholesterol
cholesterol
ceramide glucosyltransferase
mice
Gangliosidoses
Lipidoses
cats
endosomes
Endosomes
Felidae
Recycling
lysosomes
Sterols
Lysosomes
sterols

ASJC Scopus subject areas

  • Agricultural and Biological Sciences(all)

Cite this

Critical role for glycosphingolipids in Niemann-Pick disease type C. / Zervas, Mark; Somers, Kyra L.; Thrall, Mary Anna; Walkley, Steven U.

In: Current Biology, Vol. 11, No. 16, 21.08.2001, p. 1283-1287.

Research output: Contribution to journalArticle

Zervas, Mark ; Somers, Kyra L. ; Thrall, Mary Anna ; Walkley, Steven U. / Critical role for glycosphingolipids in Niemann-Pick disease type C. In: Current Biology. 2001 ; Vol. 11, No. 16. pp. 1283-1287.
@article{4cc3568d897648c69b3ce61a99034387,
title = "Critical role for glycosphingolipids in Niemann-Pick disease type C",
abstract = "Niemann-Pick type C (NPC) disease is a cholesterol lipidosis caused by mutations in NPC1 and NPC2 gene loci [1]. Most human cases are caused by defects in NPC1 [2], as are the spontaneously occurring NPC diseases in mice [3] and cats [4]. NPC1 protein possesses a sterol-sensing domain [1-3] and has been localized to vesicles that are believed to facilitate the recycling of unesterified cholesterol from late endosomes/lysosomes to the ER and Golgi [1, 5-7]. In addition to accumulating cholesterol, NPC1-deficient cells also accumulate gangliosides and other glycosphingolipids (GSLs), and neuropathological abnormalities in NPC disease closely resemble those seen in primary gangliosidoses [1, 8-12]. These findings led us to hypothesize that NPC1 may also function in GSL homeostasis [9]. To evaluate this possibility, we treated murine and feline NPC models with N-butyldeoxynojirimycin (NB-DNJ), an inhibitor of glucosylceramide synthase, a pivotal enzyme in the early GSL synthetic pathway [13, 14]. Treated animals showed delayed onset of neurological dysfunction, increased average life span (in mice), and reduced ganglioside accumulation and accompanying neuropathological changes. These results are consistent with our hypothesis and with GSLs being centrally involved in the pathogenesis of NPC disease, and they suggest that drugs inhibiting GSL synthesis could have a similar ameliorating effect on the human disorder.",
author = "Mark Zervas and Somers, {Kyra L.} and Thrall, {Mary Anna} and Walkley, {Steven U.}",
year = "2001",
month = "8",
day = "21",
doi = "10.1016/S0960-9822(01)00396-7",
language = "English (US)",
volume = "11",
pages = "1283--1287",
journal = "Current Biology",
issn = "0960-9822",
publisher = "Cell Press",
number = "16",

}

TY - JOUR

T1 - Critical role for glycosphingolipids in Niemann-Pick disease type C

AU - Zervas, Mark

AU - Somers, Kyra L.

AU - Thrall, Mary Anna

AU - Walkley, Steven U.

PY - 2001/8/21

Y1 - 2001/8/21

N2 - Niemann-Pick type C (NPC) disease is a cholesterol lipidosis caused by mutations in NPC1 and NPC2 gene loci [1]. Most human cases are caused by defects in NPC1 [2], as are the spontaneously occurring NPC diseases in mice [3] and cats [4]. NPC1 protein possesses a sterol-sensing domain [1-3] and has been localized to vesicles that are believed to facilitate the recycling of unesterified cholesterol from late endosomes/lysosomes to the ER and Golgi [1, 5-7]. In addition to accumulating cholesterol, NPC1-deficient cells also accumulate gangliosides and other glycosphingolipids (GSLs), and neuropathological abnormalities in NPC disease closely resemble those seen in primary gangliosidoses [1, 8-12]. These findings led us to hypothesize that NPC1 may also function in GSL homeostasis [9]. To evaluate this possibility, we treated murine and feline NPC models with N-butyldeoxynojirimycin (NB-DNJ), an inhibitor of glucosylceramide synthase, a pivotal enzyme in the early GSL synthetic pathway [13, 14]. Treated animals showed delayed onset of neurological dysfunction, increased average life span (in mice), and reduced ganglioside accumulation and accompanying neuropathological changes. These results are consistent with our hypothesis and with GSLs being centrally involved in the pathogenesis of NPC disease, and they suggest that drugs inhibiting GSL synthesis could have a similar ameliorating effect on the human disorder.

AB - Niemann-Pick type C (NPC) disease is a cholesterol lipidosis caused by mutations in NPC1 and NPC2 gene loci [1]. Most human cases are caused by defects in NPC1 [2], as are the spontaneously occurring NPC diseases in mice [3] and cats [4]. NPC1 protein possesses a sterol-sensing domain [1-3] and has been localized to vesicles that are believed to facilitate the recycling of unesterified cholesterol from late endosomes/lysosomes to the ER and Golgi [1, 5-7]. In addition to accumulating cholesterol, NPC1-deficient cells also accumulate gangliosides and other glycosphingolipids (GSLs), and neuropathological abnormalities in NPC disease closely resemble those seen in primary gangliosidoses [1, 8-12]. These findings led us to hypothesize that NPC1 may also function in GSL homeostasis [9]. To evaluate this possibility, we treated murine and feline NPC models with N-butyldeoxynojirimycin (NB-DNJ), an inhibitor of glucosylceramide synthase, a pivotal enzyme in the early GSL synthetic pathway [13, 14]. Treated animals showed delayed onset of neurological dysfunction, increased average life span (in mice), and reduced ganglioside accumulation and accompanying neuropathological changes. These results are consistent with our hypothesis and with GSLs being centrally involved in the pathogenesis of NPC disease, and they suggest that drugs inhibiting GSL synthesis could have a similar ameliorating effect on the human disorder.

UR - http://www.scopus.com/inward/record.url?scp=0035928841&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035928841&partnerID=8YFLogxK

U2 - 10.1016/S0960-9822(01)00396-7

DO - 10.1016/S0960-9822(01)00396-7

M3 - Article

C2 - 11525744

AN - SCOPUS:0035928841

VL - 11

SP - 1283

EP - 1287

JO - Current Biology

JF - Current Biology

SN - 0960-9822

IS - 16

ER -